Reviewer's report

Title: A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab

Version: 1 Date: 06 Feb 2018

Reviewer: Lori D. Wilson

Reviewer's report:

This manuscript is a case report of an apparently successful treatment of a patient with Allergic bronchopulmonary aspergillosis (ABPA) with Mepolizumab. Mepolizumab is a IL-5 blocking agent that may help reduce eosinophilic infiltration and inflammation. While the findings of this study are important and may help other patients with ABPA, by reducing or potential eliminating the need for high dose corticosteroids; some of the documentation used to show clinical improvements were unclear.

Specifically, in both the Abstract and body of the manuscript, improvements in FEV1 were mentioned. In some places, the absolute value of the FEV1 was only given and did not indicate either a percent predicted or the FEV1/FVC ratio. Since the absolute FEV1 is a size, age and gender dependent variable it is meaningless unless references to its predicated value or % of FVC. In several locations the FEV1/FEV was list as a percent. Was this an error? Again this is unclear. An FEV1/FVC ratio of 66.9 is much different than an FEV1 percent predicted of 66.9%. Additionally, eosinophil counts are provided as measures of improvement but do not clearly indicate if the cells are from peripheral blood or bronchial washing. All cell counts should identify the source of cells for future clinical referencing.

Some reference as to the clinical significance of an improvement in FEV1/FEV (or is it FEV1/FVC) of 66.9 to 69.2 and an FEV1 of 1.01 L to 1.25 L or 1.28L would also be very helpful.

More detail regarding the specific areas of improvement in the Asthma Control Test would also be helpful. What do scores of 18 and 24 indicated, i.e. moderate/poor control?
Any more detailed information regarding precautions or positive outcomes when transitioning from omalizumab to mepolizumab would enhance the overall quality of the manuscript. Are there any IgE precautions with mepolizumab to be aware of?

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.
No

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.
No

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.
Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:
Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interest.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal